Pixium Vision announces participation in upcoming scientific conferences in September 2022
Pixium Vision announces participation in upcoming scientific conferences in September 2022
Paris, France, August29, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following scientific conferences during September 2022:
- 22nd EURETINA Congress, September 1 - 4, Hamburg & Virtual
Lloyd Diamond, Chief Executive Officer, Ralf Hornig, PhD, Director of Clinical Affairs, and Professor Frank G. Holz, Scientific Advisor, to attend in-person. Information on registering for the conference is available here.
- Eyecelerator @ AAO 2022, September 29, Chicago
Ralf Hornig, PhD, Director of Clinical Affairs, to attend in-person. Registration for the conference is open here.
To request a one-on-one meeting with Pixium Vision please contact investors@pixium-vision.com.
About Pixium Vision
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
Forward-Looking Statements. This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors (“Facteurs de Risques”) section of the Company’s 2021 Half-Year Financial Report and other documents the Company files with the AMF, which is available on the AMF website (www.amf- france.org) or on the Company’s website.
For more information: To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.http://www.pixium-vision.com/fr
Follow us on To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.@PixiumVision; To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.facebook.com/pixiumvision
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.www.linkedin.com/company/pixium-vision
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
Contacts
| Pixium Vision Offer Nonhoff Chief Financial Officer investors@pixium-vision.com +33 1 76 21 47 68 | Media Relations LifeSci Advisors Sophie Baumont sophie@lifesciadvisors.com +33 6 27 74 74 49 | Investor Relations LifeSci Advisors Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 76 735 01 31 |
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Novo Nordisk A/S – Reduction of the share capital24.4.2024 14:48:49 CEST | Press release
Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 4,500,000. After the reduction of the share capital, the company’s share capital is nominally DKK 446,500,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 339,012,800. The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme, which will continue as previously announced. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our
cBrain takes lead within AI for government24.4.2024 14:48:40 CEST | Press release
Company Announcement no. 07/2024 cBrain takes lead within AI for government Copenhagen, April 24, 2024 cBrain (NASDAQ: CBRAIN) entered 2024 on the back of continued strong organic growth and solid earnings, reporting full-year 2023 results showing a 27% growth year-over-year and EBT (earnings before tax) of 34%. The first months of 2024 show continued business development in line with plans, winning new customers and projects in both Denmark and internationally. Consequently, cBrain maintains its expectations for 2024, forecasting full-year revenue growth of 20-25% and EBT (earnings before tax) of 24-30%. First quarter 2024 has been exciting for cBrain. While executing the growth plan, with a continued focus on F2 Climate Software as an international door opener and developing the F2-for-Partners concept, cBrain has in parallel developed a new F2 standard module for government Artificial Intelligence (AI), called F2 AI Assistant. F2 AI Assistant has been developed in close collaboratio
Vertex Selected to Join Oracle ISV Accelerator for SaaS Initiative24.4.2024 14:00:00 CEST | Press release
Vertex offers customers an optimized business operations and outcomes experience by integrating tax in and around Oracle Fusion Cloud Applications KING OF PRUSSIA, Pa., April 24, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions and a member of Oracle PartnerNetwork (OPN), today announced that it has been selected to join the Oracle Independent Software Vendor (ISV) Accelerator for SaaS Initiative. With expertise in Oracle Cloud Fusion Cloud Applications integrations, Vertex continues to leverage the power of contract and tax data to optimize customer operations and outcomes. "Building on our longstanding relationship with Oracle, we are thrilled to join the Oracle ISV Accelerator," said Bradd Wildstein, Vice President, Indirect Sales at Vertex, Inc. "Through this partnership, Vertex can now enhance our customers' finance and sales processes by integrating essential tax solutions into Oracle Fusion Application
Reminder: Program for the publication of Yara International ASA first quarter results 202424.4.2024 14:00:00 CEST | Press release
Yara International ASA first quarter 2024 results will be published on Friday, 26 April 2024 at 08:00 CEST. You can follow the presentation of first quarter results at 12:00 CEST. The presentation will be held in English. The report, presentation and webcast will be available at the above mentioned times at: https://yara.com/investor-relations/latest-quarterly-report/ There will also be a conference call at 13:00 CEST the same day with an opportunity to ask questions to Yara’s management. Please use the link to register for this session: https://registrations.events/direct/Q4I2875784 Registered conference call participants will receive a confirmation with a full list of available international dial-in numbers and a unique passcode. If you do not see the email in a few minutes after completed registration, please check the “junk mail” folder or “spam” folder in your email client. Please join the call 5-10 minutes prior to scheduled start time. Alternatively, it is possible to use the di
Huhtamaki welcomes European Parliament’s vote on EU Packaging Regulation24.4.2024 14:00:00 CEST | Press release
HUHTAMÄKI OYJ PRESS RELEASE 24.4.2024 AT 15:00 EEST The European Parliament voted to approve the Packaging and Packaging Waste Regulation (PPWR) today on Wednesday April 24, 2024. The vote followed a negotiation agreement reached on March 15 between the EU institutions on the final version of the regulation. The negotiation agreement, now endorsed by the European Parliament, brought significant changes compared to the original proposal for the regulation by the European Commission specifically in relation to restrictions of packaging formats in HORECA sector and to take-away re-use targets. “We welcome the European Parliament’s vote to move forward on this important piece of environmental legislation. The regulation includes ambitious and binding recyclability and recycling targets for the industry. We are committed to providing our customers with innovative and fully recyclable packaging solutions. We are pleased that the regulation approved today by the European Parliament respects t